Extracorporeal membrane oxygenation for pandemic H1N1 2009 respiratory failure

Minerva Anestesiol. 2010 Dec;76(12):1043-51.

Abstract

Background: Severe respiratory failure related to infection with the pandemic influenza A/H1N1 2009 virus is uncommon but possibly life-threatening. If, in spite of maximal conventional critical care, the patient's condition deteriorates, extracorporeal membrane oxygenation (ECMO) may be a life-saving procedure.

Methods: An observational study approved by the local ethics committee was carried out. Data from all patients treated with ECMO at the ECMO Center Karolinska for influenza A/H1N1 2009-related severe respiratory failure were analyzed. The main outcome measure was survival three months after discharge from our department.

Results: Between July 2009 and January 2010, 13 patients with H1N1 2009 respiratory failure were treated with ECMO. Twelve patients were cannulated for veno-venous ECMO at the referring hospital and transported to Stockholm. One patient was cannulated in our hospital for veno-arterial support. The median ratio of the arterial partial oxygen pressure to the fraction of inspired oxygen (P/F ratio: PaO2 /FiO2) before cannulation was 52.5 (interquartile range 38-60). Four patients were converted from veno-venous to veno-arterial ECMO because of right heart failure (three) or life-threatening cardiac arrhythmias (one). The median maximum oxygen consumption via ECMO was 251 ml/min (187-281 ml/min). Twelve patients were still alive three months after discharge; one patient died four days after discharge due to intracranial hemorrhage.

Conclusion: Patients treated with veno-venous or veno-arterial ECMO for H1N1 2009-related respiratory failure may have a favorable outcome. Contributing factors may include the possibility of transport on ECMO, conversion from veno-venous (v-v) or veno-arterial (v-a) ECMO if necessary, high-flow ECMO to meet oxygen requirements and active surgery when needed.

MeSH terms

  • Adult
  • Analgesics / therapeutic use
  • Cohort Studies
  • Cross Infection / therapy
  • Extracorporeal Membrane Oxygenation* / adverse effects
  • Extracorporeal Membrane Oxygenation* / instrumentation
  • Female
  • Humans
  • Hypnotics and Sedatives / therapeutic use
  • Hypoxia / therapy
  • Influenza A Virus, H1N1 Subtype*
  • Influenza, Human / complications
  • Influenza, Human / therapy*
  • Influenza, Human / virology
  • Male
  • Middle Aged
  • Pandemics
  • Pregnancy
  • Respiration, Artificial
  • Respiratory Function Tests
  • Respiratory Insufficiency / etiology
  • Respiratory Insufficiency / therapy*
  • Respiratory Insufficiency / virology
  • Treatment Outcome

Substances

  • Analgesics
  • Hypnotics and Sedatives